Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 57 results for "Emixustat Hydrochloride"

Acucela Announces Termination of Emixustat Agreement and OPA-6566 Agreement with Otsuka Pharmaceutical, and Postponement of Annual Shareholder Meeting
PharmaVOICE

Visual cycle modulator fails to meet primary endpoint of reduc...

Acucela announced that the novel investigational visual cycle modulator emixustat hydrochloride failed to reduce geographic atrophy lesion growth rate in the SEATTLE study, according to a company press release. There was no significant difference ... Healio, 2 months ago
[x]  

Subspecialty News: Humira Approved for Noninfectious Uveitis

Leaders see beyond anti-VEGF monotherapy. BY JERRY HELZNER, CONTRIBUTING EDITOR ■ Leading developers of drugs for retinal disease — including Regeneron, Roche/Genentech, and Aerpio — are pursuing what could become one of the most promising ...
 Retinal Physician1 week ago
Drug Development Technology

May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial

US-based companies ProMedica and Stemedica Cell Technologies (Stemedica), along with the family of hockey legend Gordie Howe, have planned to begin a human stem cell trial to advance the treatment of traumatic brain injury (TBI). The three-year ...
 Drug Development Technology1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Emixustat Hydrochloride
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less